A truly extraordinary case has emerged. MSD Korea has applied for the reimbursement of 13 Keytruda indications at once. This is an unprecedented event, the first time such a large amount of applications had been filed for a single drug since the positive list system was implemented for drug reimbursement in Korea.

After submitting the applications, MSD explained “Cancer is in itself an aggressive and life-threatening condition, and we saw that there was a dire need for improved access to Keytruda in the field due to the lack of alternatives or reimbursed latest treatment options. To address the need, the company decided to apply for the extended reimbursement of Keytruda to cover indications with hig